Cartalax Research Overview (also known as Cartalax peptide, Khavinson cartilage peptide, Ala-Glu-Asp-Gly tetrapeptide)
A peptide studied specifically for cartilage regeneration, joint recovery, and connective-tissue support under aging or physical stress conditions. Research interest focuses on mobility preservation and structural repair. Frequently combined with TB-500, BPC-157, and Sigumir in joint-health protocols.
What Is Cartalax?
Cartalax is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting cartilage tissue — specifically articular cartilage and intervertebral disc cartilage. It is designed to restore normal chondrocyte function in aging or degenerating cartilage through epigenetic regulation of gene expression.
Cartilage and Aging
Articular cartilage lacks blood vessels, nerves, and lymphatics — making it uniquely dependent on diffusion for nutrient supply and highly vulnerable to age-related decline. Chondrocyte activity decreases with age, collagen type II synthesis falls, proteoglycan content declines, and the balance shifts toward catabolism. This process underlies osteoarthritis, one of the most prevalent age-related conditions globally.
Research Applications
Animal studies in aged rats have shown improved histological scores of cartilage quality, increased proteoglycan content, and reduced markers of chondrocyte senescence following Cartalax administration. It is often combined with Sigumir (another joint bioregulator) in comprehensive joint health research protocols.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Room temperature in dry place |
| Timing | AM or PM, consistent daily timing |
Research Indications
Joint Health
Clinical Joint Support
Russian studies show benefits for osteoarthritis and osteochondrosis using 0.1mg capsules
Preventive Use
Used to prevent degenerative processes in elderly patients
Post-Fracture Recovery
Supports healing after bone and joint injuries
Skin Health
Fibroblast Activation
Increases skin cell proliferation and collagen production
Anti-Aging Effects
Reduces cellular senescence markers in connective tissue
Improved Microcirculation
Enhances blood flow and nutrient delivery to tissues
Cellular Health
Reduced Apoptosis
Decreases programmed cell death in aging tissues
Stem Cell Support
Maintains regenerative capacity of mesenchymal stem cells
ECM Preservation
Protects extracellular matrix from age-related breakdown
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Protocol | 1–2 mg daily | Once daily | SubQ |
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
Complementary bioregulatory effects - Cartalax for connective tissue while others target specific organs (Epitalon for pineal, Thymalin for thymus)
Cartalax may enhance collagen synthesis while oral collagen provides raw materials for tissue repair
Different mechanisms - BPC-157 for general healing, Cartalax specifically for cartilage/connective tissue
No direct interaction - TB-500 works through actin regulation while Cartalax affects fibroblast proliferation
Both affect tissue growth - monitor for excessive proliferation or unexpected tissue changes
May work well together - Cartalax supports tissue while anti-inflammatories reduce joint inflammation
Complementary joint support - traditional supplements provide building blocks while Cartalax modulates cellular activity
No specific studies on interaction - Cartalax affects cell proliferation, consult physician if on immunosuppressive therapy
Reported Research Timeline
01Week 1–2 (reported in cited studies): no significant changes, establishing baseline
02Week 3–4 (reported in cited studies): gradual improvement in joint comfort
03Month 2 (reported in cited studies): noticeable mobility improvements
04Month 3 (reported in cited studies): maximum therapeutic effect achieved
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Take with meals as directed by Russian manufacturers to optimize tolerance
No reported side effects in Russian clinical use when taken properly
Well-tolerated even in elderly patients
Can be combined with conventional treatments
No drug dependence reported
Seek Medical Attention If:
Digestive upset (rare when taken with food)
No improvement after 3 months
Quality Indicators
Verified Marker
Pharmaceutical packaging
Russian pharmaceutical products come in professional packaging with holographic seals
Verified Marker
Correct capsule content
Each capsule should contain exactly 0.1mg (100mcg) of AC-4 peptide complex
Verified Marker
Clear dosing instructions
Legitimate products include detailed Russian/English instructions specifying "with meals"
Acceptable Range
Import verification
Ensure proper import documentation for authenticity
Verified Marker
Manufacturer compliance
Follow official Russian manufacturer timing guidelines for safety and efficacy
Research Citations
Research Focus
Cartilage restoration, Joint health, Anti-aging, Collagen synthesis, Articular function
Verified Vendors Carrying Cartalax
Frequently Asked Questions
What should researchers watch for with Cartalax?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Cartalax?
Week 1–2 (reported in cited studies): no significant changes, establishing baseline
How is Cartalax typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →